ASCO 2021 Top Pick #6: Fixed-duration (FD) First-Line Treatment (Tx) with Ibrutinib (I) Plus Venetoclax (V) for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Analysis of the FD Cohort of the Phase 2 CAPTIVATE study.

You are here: